YZY Med enters into strategic cooperation with Leica Biotechnology

On December 25th, Wuhan YZY Medical Science and Technology Co., Ltd. (hereinafter referred to as “YZY Med”) and Leica Biotechnology (Shanghai) Co., LTD. (hereinafter referred to as “Leica Biotechnology”) signed a strategic cooperation agreement in Optics Valley Biomedical Accelerator, East Lake High-tech Zone, Wuhan, and officially became a strategic partner. The cooperation aims to integrate the technical and resource advantages of both parties in the fluorescence in situ hybridization (FISH) platform, and jointly promote the development and application of precision medicine technology. In order to further promote the “four modernization” process of intelligent pathology industry and improve the level of precision diagnosis and treatment of cancer in China, the two parties will make full use of the advantages of their respective molecular detection technology platforms to jointly protect the health of thousands of people! Mr. Liu, General manager of YZY Med, and Mr. Zhou, Head of BU of Leica Bio China, witnessed the important moment of strategic cooperation between the two sides as signatories.

Mr. Liu said, “Leica Biotechnology, as the world’s leading provider of pathology solutions, has a comprehensive technology platform from sample preparation and processing to digital imaging analysis. The core of this strategic cooperation is the deep integration of both parties on the fluorescence in situ hybridization (FISH) technology platform. FISH plays an important role in tumor diagnosis and prognosis evaluation due to its advantages of high sensitivity, high specificity and rapid detection.

“The collaboration between Leica Biotechnology and YZY Med will enable both parties to jointly advance more efficient and accurate FISH products and services to meet the urgent needs of clinical molecular pathology diagnosis.”

Mr. Zhou said, “As a pioneer in the field of pathological diagnosis in China in recent years, YZY Med has rich experience in the development of molecular pathological detection products, especially FISH technology. Leica Biology is pleased to enter into a strategic partnership with YZY Med in the field of rapid FISH diagnosis. We hope that the combination of the Leica platform will lead to further progress in the reliability and efficiency of fluorescence in situ hybridization technology, and jointly promote the product to primary hospitals for the benefit of patients.”

This signing marks the official launch of in-depth cooperation between the two parties in the direction of molecular pathology diagnosis and treatment. In the future, customer-oriented mutual empowerment will be carried out to put better products into the market. Adhering to the concept of win-win cooperation, both parties will give full play to their respective advantages and resources, protect life and health with high-quality products and services, and boost the continuous development of cancer precision medicine.

Share your love

Leave a Reply

Your email address will not be published. Required fields are marked *

Contact Us